Jason Smith
Net Worth
Last updated:
What is Jason Smith net worth?
The estimated net worth of Mr. Jason Smith is at least $2,701,846 as of 7 Sep 2025. He owns shares worth $356,715 as insider, has earned $317,261 from insider trading and has received compensation worth at least $2,027,870 in Real Matters Inc. and UroGen Pharma Ltd..
What is the salary of Jason Smith?
Mr. Jason Smith salary is $673,750 per year as Founder & Executive Chairman in Real Matters Inc.. He also receives $338,530 as Gen. Counsel & Chief Compliance Officer in UroGen Pharma Ltd..
How old is Jason Smith?
Mr. Jason Smith is 50 years old, born in 1975.
What stocks does Jason Smith currently own?
As insider, Mr. Jason Smith owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
UroGen Pharma Ltd. (URGN) | Gen. Counsel & Chief Compliance Officer | 18,824 | $18.95 | $356,715 |
What does UroGen Pharma Ltd. do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Jason Smith insider trading
UroGen Pharma Ltd.
Mr. Jason Smith has made 12 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,248 units of URGN stock worth $19,693 on 1 Feb 2024.
The largest trade he's ever made was exercising 8,334 units of URGN stock on 31 Aug 2023. As of 7 Sep 2025 he still owns at least 18,824 units of URGN stock.
Real Matters key executives
Real Matters Inc. executives and other stock owners filed with the SEC:
- Mr. Brian Lang (56) Chief Executive Officer & Director
- Mr. Jason Smith (50) Founder & Executive Chairman
- Mr. Robert John Smith (64) Executive Vice President of Corporation Devel.